DUBLIN--(BUSINESS WIRE)--The "Vaccine Adjuvants - Global Market Outlook (2017-2026)" report has been added to ResearchAndMarkets.com's offering.
According to this report, the Global Vaccine Adjuvants market accounted for $460.21 million in 2017 and is expected to reach $1,330.25 million by 2026 growing at a CAGR of 12.5% from 2017 to 2026.
Some of the factors such as the high occurrence of zoonotic and infectious syndromes, growing geriatric population and rising usage of Adjuvants in Vaccine are fueling the market growth. However, factors such as the cost of adjuvant development and side effects of adjuvants are hampering the market growth. The rising usage of synthetic vaccines and recombinant sub-unit are acting as an opportunity for the market growth in the coming years.
Amongst Route of Administration, Intramuscular Route segment is driven by owing to rapidly rising geriatric population and vaccines for enhanced immunization are propelling the growth of this segment. These include vaccines for HPV, influenza, meningitis, etc.
By geography, North America region is dominated the market during the forecast period due to factors such as higher adoption, greater knowledge about regular vaccination and presence of major market players, coupled with higher healthcare expenditure.
What the report offers:
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Topics Covered
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Futuristic Market Scenario
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Vaccine Adjuvants Market, By Product
5.1 Introduction
5.2 Pathogen Components
5.3 Particulate Adjuvants
5.4 Combination Adjuvants
5.5 Adjuvant Emulsions
5.6 Saponin
5.7 Other Types
6 Global Vaccine Adjuvants Market, By Disease Type
6.1 Introduction
6.2 Cancer
6.3 Infectious Diseases
6.4 Other Disease Types
7 Global Vaccine Adjuvants Market, By Type
7.1 Introduction
7.2 Virus-like Particles
7.3 Tensoactive Adjuvants
7.4 Organic Adjuvants
7.5 Mineral Salt based Adjuvants
7.6 Liposomes
7.7 Emulsions
7.8 Carbohydrates Adjuvants
7.9 Bacteria-derived Adjuvants
7.10 Other Types
8 Global Vaccine Adjuvants Market, By Mechanism of action
8.1 Introduction
8.2 Vehicle Adjuvants
8.3 Carriers
8.4 Active Immunostimulants
9 Global Vaccine Adjuvants Market, By Route of Administration
9.1 Introduction
9.2 Subcutaneous Route
9.3 Oral Route
9.4 Intranasal Route
9.5 Intramuscular Route
9.6 Intradermal Route
9.7 Other Route of Administrations
10 Global Vaccine Adjuvants Market, By Application
10.1 Introduction
10.2 Veterinary Vaccine Adjuvants
10.3 Human Vaccine Adjuvants
11 Global Vaccine Adjuvants Market, By End User
11.1 Introduction
11.2 Research Institutes
11.3 Pharmaceutical Companies
11.4 Contract Manufacturing Organization
11.5 Commercial
11.6 Pediatric
11.7 Adults
11.8 Other End Users
12 Global Vaccine Adjuvants Market, By Geography
12.1 Introduction
12.2 North America
12.2.1 US
12.2.2 Canada
12.2.3 Mexico
12.3 Europe
12.3.1 Germany
12.3.2 UK
12.3.3 Italy
12.3.4 France
12.3.5 Spain
12.3.6 Rest of Europe
12.4 Asia Pacific
12.4.1 Japan
12.4.2 China
12.4.3 India
12.4.4 Australia
12.4.5 New Zealand
12.4.6 South Korea
12.4.7 Rest of Asia Pacific
12.5 South America
12.5.1 Argentina
12.5.2 Brazil
12.5.3 Chile
12.5.4 Rest of South America
12.6 Middle East & Africa
12.6.1 Saudi Arabia
12.6.2 UAE
12.6.3 Qatar
12.6.4 South Africa
12.6.5 Rest of Middle East & Africa
13 Key Developments
13.1 Agreements, Partnerships, Collaborations and Joint Ventures
13.2 Acquisitions & Mergers
13.3 New Product Launch
13.4 Expansions
13.5 Other Key Strategies
14 Company Profiling
14.1 Viscogel AB
14.2 Vaxliant
14.3 Vaxine Pty Ltd.
14.4 Sigma Aldrich (Merck KGaA)
14.5 Sergeant Adjuvants
14.6 OZ Biosciences
14.7 Novavax, Inc.
14.8 Novartis/CSL
14.9 MVP Laboratories, Inc.
14.10 Kineta, Inc.
14.11 Invivogen
14.12 GSK
14.13 CureVac AG
14.14 CSL Limited
14.15 Avanti Polar Lipids
14.16 Aphios Corp.
14.17 Agenus, Inc.
14.18 Adjuvatis
14.19 Adjuvance Technologies, Inc
For more information about this report visit https://www.researchandmarkets.com/research/848kpq/global_vaccine?w=4
